Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Biomea Announces Pricing of Initial Public Offering
April 15, 2021 22:32 ET | Source: Biomea Fusion, Inc, Biomea Fusion, Inc, Redwood City, California, UNITED STATES
REDWOOD CITY, Calif., April 15, 2021 (GLOBE NEWSWIRE) Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock are being offered by Biomea. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Biomea, are expected to be $153.0 million. Biomea’s common stock is expected to begin trading on The Nasdaq Global Select Market on Ap
Akoya Biosciences Announces Pricing of Initial Public Offering
MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its initial public offering of 6,580,000 shares of its common stock at a price of $20.00 per share, for gross proceeds of $131.6 million, before underwriting discounts and commissions and offering expenses payable by Akoya. Akoya has also granted the underwriters a 30-day option to purchase up to an additional 987,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Akoya. The shares are expected to begin trading on the Nasdaq Global Select Market on April 16, 2021 under the ticker symbol “AKYA.” The offering is expected to close on April 20, 2021, subject to the satisfaction of customary closing conditions.
Recursion Pharmaceuticals Expands IPO to Raise $436 Million yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Recursion Pharmaceuticals Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
SALT LAKE CITY, April 16, 2021 /PRNewswire/ Recursion Pharmaceuticals, Inc. ( Recursion or we ) today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Recursion, are expected to be $436.4 million, excluding any exercise of the underwriters option to purchase additional shares. The shares are expected to begin trading on the Nasdaq Global Select Market on April 16, 2021 under the symbol RXRX and the offering is expected to close on April 20, 2021, subject to customary closing conditions. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an